Antonio Rosato
Research Interests
Explore related searches
Contact this professor
Get a free first email built on one of their papers, ready for you to edit and send yourself.
Articles (16)
The high mutation rate of SARS-CoV-2 leads to the emergence of multiple variants, some of which are resistant to vaccines and drugs targeting viral elements. Targeting host dependency factors, e.g. cellular proteins required for viral replication, would help prevent resistance. However, it remains unclear whether different SARS-CoV-2 variants induce conserved cellular responses and exploit the same core host factors. To this end, we compared three variants of concern and found that the host transcriptional response was conserved, differing only in kinetics and magnitude. Through CRISPR screening, we identified host genes required for infection by each variant. Most of the genes were shared by multiple variants. We validated our hits with small molecules and repurposed Food and Drug Administration-approved drugs. All the drugs were highly active against all the variants tested, including new variants that emerged during the study (Delta and Omicron). Mechanistically, we identified reactive oxygen species production as a key step in early virus replication. Antioxidants such as N-acetyl cysteine (NAC) were effective against all the variants in both human lung cells and a humanised mouse model. Our study supports the use of available antioxidant drugs, such as NAC, as a general and effective anti-COVID-19 approach.
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Juvenile myelomonocytic leukemia (JMML) is a rare clonal stem cell disorder that occurs in early childhood and is characterized by the hyperactivation of the RAS pathway in 95% of the patients. JMML is characterized by a hyperproliferation of granulocytes and monocytes, and little is known about the heterogeneous nature of leukemia-initiating cells, as well as of the cellular hierarchy of the JMML bone marrow. In this study, we report the generation and characterization of a novel patient-derived three-dimensional (3D) in vitro JMML model, called patient-derived JMML Atypical Organoid (pd-JAO), sustaining the long-term proliferation of JMML cells with stem cell features and patient-specific hallmarks. JMML cells brewed in a 3D model under different microenvironmental conditions acquired proliferative and survival advantages when placed under low oxygen tension. Transcriptomic and microscopic analyses revealed the activation of specific metabolic energy pathways and the inactivation of processes leading to cell death. Furthermore, we demonstrated the pd-JAO–derived cells’ migratory, propagation, and self-renewal capacities. Our study contributes to the development of a robust JMML 3D in vitro model for studying and defining the impact of microenvironmental stimuli on JMML disease and the molecular mechanisms that regulate JMML initiating and propagating cells. Pd-JAO may become a promising model for compound tests focusing on new therapeutic interventions aimed at eradicating JMML progenitors and controlling JMML disease.
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2022
Year:
2021
Year:
2020
Year:
2020
Collaborators (16)
Andrej Ozaniak
Charles University
Federica Collino
University of Milan
Debora Carpanese
Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico
Cristiano Salata
Associate professor in Microbiology and Clinical Microbiology
University of Padova
Maria Chiara Scaini
Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico
Cristina Poggiana
Istituto Oncologico Veneto IOV-IRCCS
Santina Quarta
University of Padua
Luca Persano
University of Padova
Ilaria Frasson
Assistant Professor
University of Padova
Giulio Fracasso
University of Padua
CRISTINA MARZANO
Associate Professor
University of Padua
Graziano Martello
University of Padua
Maria Vittoria Dieci
University of Padova
Roberta Sommaggio
University of Padua
Silvia Bresolin
-
Stefano Moro
Professor of Medicinal Chemistry
University of Padova
Make your next move.
Prepare your application
Review drafts before you send them.